Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569305 | 0.96 | ALDH1A1 (0.56) | ALDH1A1TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL4351612 | 0.80 | TDP1 (0.66) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6790333 | 0.80 | TDP1 (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2604742 | 0.78 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL8863154 | 0.78 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL8862878 | 0.78 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL8863094 | 0.78 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL8862728 | 0.78 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL6777483 | 0.78 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL10913065 | 0.78 | MAPT (0.59) | ALDH1A1TDP1L3MBTL1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-1904460-B1 | MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY | BRACCO IMAGING SPA (IT) | 2012-05-16 | — | — | EP | disclosed |
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| US-7988950-B2 | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents | BRACCO IMAGING S.P.A. (IT) | 2011-08-02 | — | — | US | disclosed |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | BRACCO IMAGING SPA (IT) | 2007-11-08 | — | — | US | disclosed |
| EP-1786475-A2 | 1,4-BIS(CARBOXYMETHYL)-6-[BIS(CARBOXYMETHYL)AMINO]-6-METHYL-PERHYDRO-1,4-DIAZEPINE (AAZTA) DERIVATIVES AS LIGANDS IN HIGH RELAXIVITY CONTRAST AGENTS FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) | Bracco Imaging, S.P.A. (IT) | 2007-05-23 | — | — | EP | disclosed |
| EP-1765812-A1 | CONTRAST AGENTS ENDOWED WITH HIGH RELAXIVITY FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) WHICH CONTAIN A CHELATING MOIETY WITH POLYHYDROXYLATED SUBSTITUENTS | Bracco Imaging, S.P.A. (IT) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006136564-A1 | MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY | BRACCO IMAGING S.P.A. (IT) | 2006-12-28 | — | — | WO | disclosed |
| US-20060034773-A1 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2006-02-16 | — | — | US | disclosed |
| WO-2006002873-A2 | 1 , 4 -BIS (CARBOXYMETHYL) -6- ' BIS ( CARBOXYMETHYL) AMINO ! -6 -METHYL- PERHYDRO-1 , 4 DIAZEPINE (AAZTA) DERIVATIVES AS LIGANDS IN HIGH RELAXIVITY CONTRAST AGENTS FOR USE IN MAGNETIC RESONANCE IMAGING (MRI ) | BRACCO IMAGING SPA (IT) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006002875-A1 | CONTRAST AGENTS ENDOWED WITH HIGH RELAXIVITY FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) WHICH CONTAIN A CHELATING MOIETY WITH POLYHYDROXYLATED SUBSTITUENTS | BRACCO IMAGING SPA (IT) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006002874-A1 | CONTRAST AGENTS ENDOWED WITH HIGH RELAXIVITY FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) WHICH CONTAIN 1, 4, 7, 10-TERTRAAZACYCLODECAN-1, 4, 7-TRIACETIC ACID CHELATING MOIETY WITH POLYHYDROXYLATED SUBSTITUENTS | BRACCO IMAGING SPA (IT) | 2006-01-12 | — | — | WO | disclosed |
| CN-1073993-C | Process for preparing bis (ether anhydrides) using alkylamine derived bismides having low melting temperatures | GEN ELECTRIC (US) | 2001-10-31 | — | — | CN | disclosed |
| CN-1121514-A | Process for preparing bis (ether anhydrides) using alkylamine derived bismides having low melting temperatures | GEN ELECTRIC (US) | 1996-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034773-A1 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | SSTR3, MB, CA13 | ALDH1A1 2501/4885TDP1 4539/4885L3MBTL1 1863/4885 |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | SLC40A1, SLC67A1, SLC19A1 | ALDH1A1 2186/4885TDP1 1664/4885L3MBTL1 3245/4885 |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | RXFP1, SLC5A7, SLC40A1 | ALDH1A1 2843/4885TDP1 1659/4885L3MBTL1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.